The AGM approved the compensation to the Board in accordance with the nomination committee's proposal.

Ernst & Young was elected as new auditor of Sobi until the end of the annual general meeting 2015.

Principles for remuneration for the management, long-term incentive program and transfer of own shares

The AGM approved the proposed guidelines for remuneration for the management.

The AGM also approved the Board's proposal regarding the implementation of a long-term incentive program, and hedging arrangements in respect of the program including a directed issue of no more than 396,180 series C shares, authorisation for the Board to decide on a repurchase of all issued series C shares and transfers of no more than 1,100,235 own common shares to program participants.

The Board's proposal regarding transfer of no more than 338,766 own common shares on the stock exchange for the purpose of covering certain payments, mainly social security contributions, that may occur in relation to the Share Program 2011 and the CEO Share Program 2011, was also approved by the AGM.

For full details on each proposal adopted by the AGM please refer to www.sobi.com.

About Sobi

Sobi is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Inflammation and Genetic diseases, with two late stage biological development projects within Haemophilia. We also market a portfolio of specialty and rare disease products for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2013, Sobi had total revenues of SEK 2.2 billion ($334 M) and about 550 employees. The share (STO:SOBI) is listed on NASDAQ OMX Stockholm. More information is available at www.sobi.com.

Easily Send & Share Press Releases

GlobeNewswire, a NASDAQ OMX company, is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.